• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Screening and Rx in Barrett Esophagus


Societal recommendations include surveillance esophagogastroduodenoscopy every 3 to 5 years for patients with Barrett esophagus, and proton pump inhibitor therapy for symptom control.

A 42-year-old man with chronic GERD symptoms undergoes an upper endoscopy, which demonstrates salmon-colored tongues that extend 2 cm above the squamocolumnar junction. Biopsies reveal intestinal metaplasia without any dysplasia. Which of the following would you recommend?

a.    Ablative therapy for the Barrett tissue
b.    Continue proton pump inhibitors; no further endoscopy required
c.    Surveillance EGD every 3 years
d.    Refer for a Nissen fundoplication


Biopsies reveal that this patient has intestinal metaplasia, which confirms the diagnosis of Barrett esophagus. Importantly, biopsy reveals that he has no dysplasia. Therefore, societal recommendations include surveillance esophagogastroduodenoscopy every 3 to 5 years. He should also continue proton pump inhibitors for symptom control. There is no evidence to support ablative therapies for non-dysplastic Barrett esophagus. A fundoplication would not reverse the endoscopic changes of Barrett esophagus.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.